praxis biologics inc said began its initial public common stock offering 750 000 shares dlrs share company said proceeds offering will used fund product research and development including clinical testing said money will also used cover acquisition construction and equipment costs and for working capital offering being managed shearson lehman bros inc and merrill lynch capital markets company said reuter 